Monroe Capital Provides $27 Million for CNS Network Sale
Monroe Capital LLC announced the funding of a $27 million unitranche facility to support the sale of Collaborative Neuroscience Network (CNS Network) to a 100% employee stock ownership plan-owned corporation.
This is the first transaction completed by Monroe Capital’s newly-formed national ESOP lending practice. ESOPs offer corporate and individual level tax advantages that are not typically available in traditional third party sales.
Garden Grove, CA-based CNS Network is a clinical trial research provider, assisting pharmaceutical companies and contract research organizations with the various phases of drug development. The company provides services that manage various aspects of clinical trials for pharmaceutical companies testing potential compounds and drugs for FDA approval.
Monroe Capital is a provider of senior and junior debt and equity co-investments to middle-market companies in the U.S. and Canada.